TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02858544

Intervention type: OTHER
Intervention: The Concussion Identification Index
Description: Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms

Intervention type: OTHER
Intervention: The Concussion Identification Index
Description: Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms

Intervention type: OTHER
Intervention: ImPACT
Description: Patient- completed computerized neurocognitive test battery

Intervention type: OTHER
Intervention: ImPACT
Description: Patient- completed computerized neurocognitive test battery
Study: NCT03391193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-dose Quadrivalent Influenza Vaccine
Description: 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-dose Quadrivalent Influenza Vaccine
Description: 0.5 mL, intramuscular
Study: NCT00879008

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
Study: NCT00001131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
Study: NCT01984762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Description: RYGBP=Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: SG = sleeve gastrectomy
Study: NCT00711516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
Study: NCT01431209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT05456282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
Study: NCT00626470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of TSP to DHS
Description: All patients operated with DHS. Of these two groups. One operated with TSP and one without.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of TSP to DHS
Description: All patients operated with DHS. Of these two groups. One operated with TSP and one without.
Study: NCT00497809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
Study: NCT01830400

Intervention type: DRUG
Intervention: Eslicarbazepine Acetate tablets
Description: The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
Study: NCT03642704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reinforced preventive ARV therapy
Description: If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.
Study: NCT03339297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 6.25 mg/kg via 2-hour IV infusion every 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Administered according to local institutional guidelines, physician preference, and patient need.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Administered according to local institutional guidelines, physician preference, and patient need.
Study: NCT04426695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered intravenously (IV) single dose
Study: NCT02320201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator (TENS)
Description: Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
Study: NCT04426695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV Single Dose
Study: NCT02688647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: Treatment/drug as determined by each subject's prescribing physician
Study: NCT04589598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoral Neck System
Description: femoral neck system using bolt and antirotation screw with one/two hole plate
Study: NCT03026348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Buffer
Study: NCT01962038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Aerobic and Resistance Exercise
Description: Gym and home based aerobic and resistance exercises
Study: NCT03026348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Buffer
Study: NCT01962038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercises
Description: Gym and home based stretching exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Group-based cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Group-based cognitive training
Study: NCT06311318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower eyelid massage
Description: The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
Study: NCT04040491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.

Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
Study: NCT01724619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] fluorinated dihydrotestosterone (FDHT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] fluorinated dihydrotestosterone (FDHT)
Study: NCT01489241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
Study: NCT03746288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAN008
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
Study: NCT00514852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose and Glycerin based artificial tear
Description: 1 to 2 drops into each eye as needed but at least twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: 1 to 2 drops into each eye as needed but at least twice daily
Study: NCT02581150

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of Occlusive Arterial Disease
Description: Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of Occlusive Arterial Disease
Description: Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
Study: NCT02086032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg 17 beta-estradiol
Description: Comparing sleeping quality between micronized progesterone and dydrogesterone users.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg 17 beta-estradiol
Description: Comparing sleeping quality between micronized progesterone and dydrogesterone users.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users
Study: NCT03316911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MKit
Description: MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
Study: NCT01875679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Surgical Coaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgical Training
Description: Surgical training as per participant's residency program
Study: NCT04635605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Study: NCT05449015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% atropine
Description: Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% atropine
Description: Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
Study: NCT00959400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal
Description: Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
Study: NCT04704362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ensuring Quality in Psychological Support
Description: Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training and Supervision
Description: Trainees are trained using a manual for non-specialist-delivered psychological interventions.
Study: NCT00684047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS Grifols
Description: Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS Grifols
Description: Fibrin Sealant Grifols (FS Grifols). Primary Part (II)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Manual Compression. Primary Part (II)
Study: NCT00448396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study: NCT04589598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Cannulated Screw
Description: multiple cannulated screw using 3 or 4 cannulated screw
Study: NCT03073746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Search

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Search
Study: NCT00699179

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
Study: NCT04139122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0132
Description: SJP-0132 is administered as an eye drop
Study: NCT03657771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DED
Description: DED: Diet eliminating dairy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FREE
Description: FREE: Diet eliminating dairy and food additives
Study: NCT03355469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Exercise + Metformin
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Exercise + Metformin
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Intensity Exercise + Placebo
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High Intensity Exercise + Placebo
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
Study: NCT02836509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study: NCT02965768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl
Description: 4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone HCl
Description: 4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
Study: NCT03340103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LUTEIN ofta 0,5 gocce
Description: LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
Study: NCT04139122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0132
Description: SJP-0132 is administered as an eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as an eye drop
Study: NCT02872220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y51 002 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 V27 104 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride [NaCl]
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study: NCT02817477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Delivered intranasally using an atomizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Delivered either as an IM injection or a slow IV bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Delivered either as an IM injection or a slow IV bolus
Study: NCT04139122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as an eye drop
Study: NCT01245088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chondroitin sulfate
Description: 400 mg orally three times daily for 8 weeks
Study: NCT01607203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl Daily
Description: Decapeptyl 0.2 mg SC once 1day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnyl
Description: 5000 IU SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnyl
Description: 5000 IU SC
Study: NCT03849391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skate group
Description: This group takes 500 mg/day Skate Skin extract for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 500 mg/day Placebo for 12 weeks
Study: NCT01853488

Intervention type: RADIATION
Intervention: DXA
Description: Osteodensitometry

Intervention type: RADIATION
Intervention: DXA
Description: Osteodensitometry

Intervention type: RADIATION
Intervention: pQCT
Description: Osteodensitometry

Intervention type: RADIATION
Intervention: pQCT
Description: Osteodensitometry